Rapport’s oral drug licensed from J&J cleared a Phase 2 bipolar mania study, paving the way for registrational trials next year.
endpoints.newsRapport says drug it licensed from J&J clears Phase 2 bipolar mania studyRapport’s RAP-219, licensed from J&J, hits Phase 2 bipolar mania goal, with registrational trials planned for 2H 2027.
0 reposts0 likes